6, 7 It was recently approved by US Food and Drug Administration in combination with fulvestrant for the treatment of estrogen receptor ER positive, human epidermal growth factor receptor HER 2 negative advanced or metastatic breast cancer progressing after prior endocrine therapy, 8 and in combination with letrozole as first line treatment in postmenopausal
6, 7 It was recently approved by US Food and Drug Administration in combination with fulvestrant for the treatment of estrogen receptor ER positive, human epidermal growth factor receptor HER 2 negative advanced or metastatic breast cancer progressing after prior endocrine therapy, 8 and in combination with letrozole as first line treatment in postmenopausal